

Curriculum Vitae

1. Personal Data

NAME :SI HYUN BAE, M.D.
ADDRESS :Department of Internal Medicine,
The Catholic University of Korea

2. Education (above college level) :

Mar. 1984 - Feb. 1985 :
Premedical course at The Catholic University of Korea, College of Medicine
Mar. 1986 - Feb. 1990 :
The Catholic University of Korea, College of Medicine
Mar. 1992 - Feb. 1994 : Graduate School, The Catholic University of Korea;
Master (Med. Sci)
Mar. 1994 - Feb. 2000 : Graduate School, The Catholic University of Korea ;
Ph.D. (Med. Sci)

3. Degree:

Feb. 1990 : Doctor of Medicine (M.D.)
Feb. 1994 : Master of Medical Science
Aug. 2000 : Ph.D. (Medical Science)

4. Clinical & Research Training:

March 1990 - Feb. 1991 : Internship, Kangnam St. Mary's Hospital
March 1991 - Feb. 1995 : Residency, Department of Internal Medicine,
Kangnam St. Mary's Hospital, The Catholic University of Korea
August 2002 - Feb 2002: Research Fellow, Pathology, Immunology and Laboratory Medicine,
College of Medicine, University of Florida, USA

5. Hospital Career:

March 1998 - Feb. 1999:	Clinical Fellow, Kangnam St. Mary's Hospital
March 1999 - Feb. 2001:	Instructor, St. Vincent's Hospital
March 2001 - March 2005:	Assistant Professor, Kangnam St. Mary's Hospital
April 2005 - March 2010:	Associate Professor, Kangnam St. Mary's Hospital
April 2005 - Feb. 2018	Professor, Seoul St. Mary's Hospital,
March 2018 - present	Professor, St. Paul's Hospital

6. Academic Activities

- Dec 2009 - Nov 2011: Director of the Public Relations Committee,
Korean Association for the Study of the Liver (KASL)
- July 2012 - June 2013: Secretary General, Korean Liver Cancer Association
(KLCA)
- Dec 2013 - Nov 2015: Director of the Liaison Committee, KASL
- Dec 2015 - Nov 2017: Director of the Education Committee,
Korean Society of Gastroenterology
- Dec 2017 - Secretary General, KASL

7. Licensure and Certification:

- 1990: Korean Medical License (No. 41924)
- 1995: Certification for Korean Board of Internal Medicine (No. 4436)
- 2000: Certification for Korean Society of Gastroenterology (1-01-489)
- 2001: Certification for Korean Society of Gastrointestinal Endoscopy (99-571)
- 2013: Certification for Korean Association of Clinical Ultrasound

8. Academic Honors and Awards :

- May 2000: Young Investigator Award from Asia-Pacific Association for the Study of the Liver
(APASL, Japan)
- Sept. 2000: Young Investigator Award from Asia-Pacific Digestive Week (APDW, Hongkong)
- May 2004: Best Poster Presentation Award from Asia-Pacific Association for the Study of the
Liver (APASL, India)
- May 2010: Best Original Article from The Korean Association of Internal Medicine Title: Assessment of the
Efficacy of reducing Peginterferon Alfa-2a and Ribavirin Dose on Virological response in Koreans with
Chronic hepatitis C
- December 2010: Best Poster Presentation Award from Asia-Pacific Association for the Study of the
Liver (7th APASL-STC, Chiba, Japan) Title: The response of reducing dose of Peginterferon alfa-2a
in Koreans with chronic hepatitis C genotype

Nov 2012: The Best Award of the Original Article from The Korean Association for Study of the Liver. The title: Differences in the patterns and outcomes of enhanced viral replication between hepatitis C virus and hepatitis B virus in patients with hepatocellular carcinoma during transarterial chemolipiodolization. Korean J Hepatol. 2011 Dec;17(4):299-306.

June, 2018: GlaxoSmithKline Research Award of The Korean Association for Study of the Liver. The title: A comparative study of sorafenib and metronomic chemotherapy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma with poor liver function. Clin Mol Hepatol. Clin Mol Hepatol. 2017 ;23(2):128-137.

9. Grants

- Apr. 2004: Grant from the Ministry of Health and Welfare (955,800 dollars for 6 years)
- May. 2005: Grant from the Ministry of Health and Welfare (5,926,000 dollars for 9 years)
- Apr. 2006: Grant from the Ministry of Health and Welfare (280,000 dollars for 8 years)
- Dec. 2006: Grant from the Catholic University (30,000 dollars for 3 years)
- May, 2008: Grant from the Korea Centers for Disease Control and Prevention (40,000 dollars/years)
- Nov, 2008: Grant from the Ministry of Health and Welfare (60,000 dollars/year for 2 years)
- Sep. 2009: Grant from the Catholic University (8,600 dollars for 2 years)
- May. 2011: Grant from the Ministry of Health and Welfare (200,939,000 dollars for 2 years)
- Apr. 2012: Grant from the Ministry of Health and Welfare (150,000 dollars/years)
- Nov, 2013: Grant from the Ministry of Health and Welfare (2,910,000 dollars for 3 years)
- May. 2015: Grant from the Ministry of Health and Welfare (105,000 dollars for 2 years)
- Aug. 2015: Grant from the Ministry of Health and Welfare (173,040 dollars for 2 years)
- Nov. 2015: Grant from the Ministry of Health and Welfare (2,643,000 dollars for 3 years)
- Mar, 2017: Grant from the Ministry of Science, ICT and Future Planning (100,000 dollars/year for 3 years)
- Apr, 2017: Grant from the Ministry of Health and Welfare (112,500 dollars/year for 3 years)

시작일	종료일	연구제목	연구비수령실적		개인공통
			지급기관	지급액	
2004.05.01	2010.04.30	기능성 세포치료제 개발 센터: 7 세부과제 (혈액줄기세포의 전이분화를 통한 췌장 베타세포 및 간세포 개발)	보건복지부	955,800,000	참여연구원
2005.05.01	2014.03.31	국내 간경변증의 현황 및 간경변증 환자의 생존율, 예후에 관한 임상연구	보건복지부	5,926,000,000	참여연구원
2006.04.01	2014.03.31	난치성 진행성 간세포암에서 간동맥내 항암 주입요법의 효능 평가를 위한 대규모 전향적 무작위 임상연구	보건복지부	280,000,000	세부연구책임자

2006.12.01	2009.11.30	in vitro 에서 중간엽줄기세포로부터 기능성 간세포분화로의 최적 분화 조건 확립	가톨릭대학교 - 성의	30,000,000	연구책임자
2008.05.01	2009.04.30	HCV에 의한 만성 간질환 환자의 코호트 연구	질병관리본부	40,000,000	연구책임자
2008.11.01	2010.10.31	비대상성 간경변증 환자에서 자가 골수유래 중간엽줄기세포 이식에 대한 임상연구	보건복지부	120,000,000	연구책임자
2009.09.01	2011.08.31	혈액줄기세포에 전이분화를 통한 간세포 개발 및 간부전 구제 기술 개발	가톨릭대학교 - 성의	8,600,000	연구책임자
2011.05.01	2013.03.31	수술적 및/또는 비수술적 치료를 받은 간세포암 환자를 대상으로 대조군과 크레아틴-에치씨씨 (자가유래 성숙화 수지상세포)	보건복지부	200,939,000	임상시험 연구 책임자
2012.04.01	2013.05.31	간암에서의 DLK1, soluble DLK1 의 발현과 임상적 예후와의 관계성 검증	보건복지부	150,000,000	연구책임자
2013.11.01	2016.05.31	임상시험 글로벌선도센터 컨소시엄의 공개형 지원 인프라 구축	보건복지부	2,910,000,000	참여연구원
2015.05.01	2017.01.31	간경화증 환자에서 간세포암 감시검사로서 6개월 간격 초음파 검사와 1년 간격 비조영 자기공명영상의 비교 연구	보건복지부	105,000,000	참여연구원
2015.08.01	2017.01.31	전향적, 무작위 배정을 이용한 간의 악성 종양의 고주파열치료 시 동영상융합기능의 유용성 연구	보건복지부	173,040,000	참여연구원
2015.11.01	2018.07.31	Pexa-Vec(펙사벡)의 진행성 간세포암 대상 글로벌 제 3 상 임상시험 프로세스 관리	보건복지부	2,643,000,000	참여연구원
2017.03.01	2020.02.29	간세포암에서 CD44/전환성장인자-베타의 조절을 통한암줄기세포를 억제하는 마이크로 RNA 발굴	미래창조과학부	300,000,000	연구책임자
2017.04.01	2019.12.31	간 섬유화 모델에서 중간엽줄기세포의 간세포분화 조절 유전자 발굴 및 항섬유화 기전 규명	보건복지부	337,500,000	연구책임자

10. Clinical Research Experience

L-FMAU-301,302,303 :Aug2004-2005

ADF103814 :JAN2005- Feb2006

ADF108005 :Aug2006-2008, Nov

CJ-OPZ2001 :Feb2006-2008, Apr

phaseIII, hepatitis B(Entecavir,022,901,049),Dec2001-present

phaseIV, hepatitis C(Peginterferon alfa-2a),Mar2003-2005Mar

phaseIII hepatitis B(LB80380),Mar2004-Jun 2006

Heptaplatin:Apr 2002-Jul 2004

Chronic hepatitis B related advanced fibrosis or cirrhosis(ADF104080) JUN 2005-2009

phaseIV, hepatitis B The **REALM study**: randomized,observational study of

entecavir to assess long-term outcomes associated with nucleoside/nucleotide monotherapy for

patients with chronic HBV infection:2007 JUL- present

phase I, hepatitis B (HB-110):2002007 JUL- 2009-2010

phase III hepatitis B :An open label study of adefovir for the treatment of patients with chronic hepatitis B related advanced fibrosis or cirrhosis (ADF104070):2005 MAY- 2009

GIDEON:global investigation of therapeutic decisions in hepatocellular carcinoma And of its treatment with sorafenib Apr,2009-present

LB80380 (ANTI-HBV) A phase 2b :2009.07-2010

SACTS ;asia of combination of tace with sorafenib in HCC pt,s:2009.7-

CA182-033 :The BRISK FL Study (HCC):2009/07-

DEFINE:A1463-111: phase III hepatitis B ETV versus ADV 2009/07-

LG-BVCL007: phase 2 LB80380 versus ETV: 2009/08-2011/05/30

CreaVax-HCC-002 phase 2 2010/05/01-

CA182-037; The BRISK FL Study (HCC):2009/07

LG-BVCL008; phase 2 LB80380 versus ETV: 2010/08-

TSU-68 phase III ; TSU-68 combination with TACE with unresectable HCC 2011/03/15~

Clinical Usefulness of combining biomarkers (AFP, AFP-L3, and PIVKA-II) with abdominal sonography or computed tomography for early detection of hepatocellular carcinoma 2016.08.30.~

Randomized, Open-label, Multi-center and Phase 2 clinical trial to evaluate the efficacy and safety of 'Immuncell-LC' in the patients undergone TACE for hepatocellular carcinoma 2017.03.01.~

A Phase 2, Randomized, Open-Label, Active-Controlled Study to Evaluate the Safety and Antiviral Activity of GS-9992 Plus Tenofovir Alafenamide (TAF) for 12 Weeks in Chronic Hepatitis B (CHB) Subjects ;2018.02.05.~

A Randomized, Multi-center Phase III Study of Nivolumab versus Sorafenib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma ;2016.02.15.~

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Safety and Efficacy of GS-9620 in combination with Tenofovir Disoproxil Fumarate (TDF) for the Treatment of Subjects with Chronic Hepatitis B and who are currently not on Treatment ;2015.11.24.~



A Phase 3 Randomized, Open-Label Study Comparing Pexa-Vec(Vaccinia GM-CSF/Thymidine Kinase-Deactivated Virus) Followed by Sorafenib Versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma(HCC) Without Prior Systemic Therapy 2016.01.05.~

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267(ABT-450/r/ABT-267) and ABT-333 in Treatment-Naive and Treatment Experienced, Non-Cirrhotic Asian Adults with Subgenotype 1b Chronic Hepatitis C Virus(HCV) Infection; 2015.05.20.~ 2017.03.31.

Efficacy and safety of daclatasvir and asunaprevir in patients with genotype 1b HCV infection who underwent prior treatment for hepatocellular carcinoma ;2017.02.07.~

A Randomized, Controlled Phase III Trial of Sorafenib with or without Conventional Transarterial Chemoembolization in Patients with Advanced Hepatocellular Carcinoma ;2013.03.05.~2017.12.31.

A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of GS-4774 in combination with Tenofovir Disoproxil Fumarate (TDF) for the Treatment of Subjects with Chronic Hepatitis B and who are currently not on Treatment ;2014.11.10.~

An Open-Label Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Treatment-Naïve and Treatment-Experienced Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With Compensated Cirrhosis and With or Without Human Immunodeficiency Virus Co-Infection ;2017.12.07.~

An Open-label, Randomized, Active Control Study to Demonstrate Non-Inferiority in Efficacy, and to Compare Safety and Tolerability of P1101 + Ribavirin to PEG-Intron + Ribavirin in Treatment-Naive Subjects with Chronic HCV Genotype 2 Infection ; 2015.12.01.~

Efficacy of tenofovir disoproxil fumarate treatment in chronic hepatitis B patient in real life ;2015.04.06.~2017.04.05

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH) ;2017.08.25.-

**A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Enzalutamide in Subjects with Advanced Hepatocellular Carcinoma ;
2015.11.01.~2018.03.31**

9. Membership in Scientific Societies:

- 1990 ~ Present Member of Korean Medical Association
- 1991 ~ Present Member of Korean Academy of Internal Medicine
- 1996 ~ Present Member of Korean Society of Gastroenterology
- 1998 ~ Present Member of Korean Society of Gastrointestinal Endoscopy
- 1998 ~ Present Member of Korean Liver Cancer Study Group
- 1998 ~ Present Member of Korean Association for the Study of The Liver
- 2008 ~ Present Member of International Liver Cancer Association
- 2008 ~ Present Member of Asia-Pacific Association for the Study of the Liver

10. Bibliography:

(최근 5년 책임저자)

1. Choi JH, Chung WJ, Bae SH, Song DS, Song MJ, Kim YS, Yim HJ, Jung YK, Suh SJ, Park JY, Kim DY, Kim SU, Cho SB. Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis. *Cancer Chemother Pharmacol.* 2018 Sep;82(3):469-478.
2. Seo KI, Bae SH, Sung PS, Park CH, Lee HL, Kim HY, Kim HJ, Jang BH, Jang JW, Yoon SK, Choi JY, Park IY, Lee J, Lee HS, Kim SJ, Kwon JH, Chang UI, Kim CW, Jo SH, Young Lee YL, Tekle F, Kim JH. Effect of antiviral therapy in reducing perinatal transmission of hepatitis B virus and maternal outcomes after discontinuing them. *Clin Mol Hepatol.* 2018 Jun 26.
3. Yoo SH, Kwon JH, Nam SW, Kim HY, Kim CW, You CR, Choi SW, Cho SH, Han JY, Song DS, Chang UI, Yang JM, Lee HL, Lee SW, Han NI, Kim SH, Song MJ, Hwang S, Sung PS, Jang JW, Bae SH, Choi JY, Yoon SK. Early development of de novo hepatocellular carcinoma after direct-acting agent therapy: Comparison with pegylated interferon-based therapy in chronic hepatitis C patients. *J Viral Hepat.* 2018 Apr 16.

4. Sung PS, Park HL, Yang K, Hwang S, Song MJ, Jang JW, Choi JY, Yoon SK, Yoo IR, Bae SH. (18)F-fluorodeoxyglucose uptake of hepatocellular carcinoma as a prognostic predictor in patients with sorafenib treatment. *Eur J Nucl Med Mol Imaging*. 2018 Mar;45(3):384-391
5. Lee HL, Bae SH, Jang B, Hwang S, Yang H, Nam HC, Sung PS, Lee SW, Jang JW, Choi JY, Han NI, Song BJ, Lee JW, Yoon SK. Reactivation of Hepatitis C Virus and Its Clinical Outcomes in Patients Treated with Systemic Chemotherapy or Immunosuppressive Therapy. *Gut Liver*. 2017 15;11(6):870-877.
6. Yang H, Woo HY, Lee SK, Han JW, Jang B, Nam HC, Lee HL, Lee SW, Song DS, Song MJ, Oh JS, Chun HJ, Jang JW, Lozada A, Bae SH, Choi JY, Yoon SK. A comparative study of sorafenib and metronomic chemotherapy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma with poor liver function. *Clin Mol Hepatol*. 2017 ;23(2):128-137.
7. Park NR, Cha JH, Jang JW, Bae SH, Jang B, Kim JH, Hur W, Choi JY, Yoon SK. Synergistic effects of CD44 and TGF- β 1 through AKT/GSK-3 β / β -catenin signaling during epithelial-mesenchymal transition in liver cancer cells. *Biochem Biophys Res Commun*. 2016 2;477(4):568-74.
8. Song MJ, Bae SH, Lee JS, Lee SW, Song do S, You CR, Choi JY, Yoon SK. Combination transarterial chemoembolization and radiofrequency ablation therapy for early hepatocellular carcinoma. *Korean J Intern Med*. 2016 ;31(2):242-252.
9. Suk KT, Yoon JH, Kim MY, Kim CW, Kim JK, Park H, Hwang SG, Kim DJ, Lee BS, Lee SH, Kim HS, Jang JY, Lee CH, Kim BS, Jang YO, Cho MY, Jung ES, Kim YM, Bae SH, Baik SK. Transplantation with autologous bone marrow-derived mesenchymal stem cells for alcoholic cirrhosis: Phase 2 trial. *Hepatology*. 2016;64(6):2185-2197
10. Song DS, Song MJ, Bae SH, Chung WJ, Jang JY, Kim YS, Lee SH, Park JY, Yim HJ, Cho SB, Park SY, Yang JM. A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. *J Gastroenterol*. 2015 ; 50(4):445-54.
11. Song MJ, Bae SH, Chun HJ, Choi JY, Yoon SK, Park JY, Han KH, Kim YS, Yim HJ, Um SH, Chung WJ, Hwang JS, Cho SB, Eun JR. A randomized study of cisplatin and 5-FU hepatic arterial



infusion chemotherapy with or without adriamycin for advanced hepatocellular carcinoma. *Cancer Chemother Pharmacol.* 2015;75(4):739-46.

12. Lee JE, Bae SH, Choi JY, Yoon SK, You YK, Lee MA. Epirubicin, Cisplatin, 5-FU combination chemotherapy in sorafenib-refractory metastatic hepatocellular carcinoma. *World J Gastroenterol.* 2014 7;20(1):235-41.

13. Song MJ, Bae SH. Newer treatments for advanced hepatocellular carcinoma. *Korean J Intern Med.* 2014 ;29(2):149-55.

14. Park CH, Bae SH, Kim HY, Chun HJ, Kim JS, Song MJ, Choi JY, Yoon SK, Han NI, Lee YS. Hepatobiliary and pancreatic: bleeding duodenal ulcer associated with coil migration after transarterial chemoembolization and radiotherapy. *J Gastroenterol Hepatol.* 2014 ;29(5):897.

15. Park CH, Bae SH, Kim HY, Kim JK, Jung ES, Chun HJ, Song MJ, Lee SE, Cho SG, Lee JW, Choi JY, Yoon SK, Han NI, Lee YS. A pilot study of autologous CD34-depleted bone marrow mononuclear cell transplantation via the hepatic artery in five patients with liver failure. *Cytotherapy.* 2013;15(12):1571-1579.

16. Song MJ, Bae SH, Lee SW, Song DS, Kim HY, Yoo IR, Choi JI, Lee YJ, Chun HJ, Lee HG, Choi JY, Yoon SK. (18)F-Fluorodeoxyglucose PET/CT predicts tumour progression after transarterial chemoembolization in hepatocellular carcinoma. *Eur J Nucl Med Mol Imaging.* 2013;40(6):865-73.

17. Park CH, Bae SH, Kim HY, Kim JK, Jung ES, Chun HJ, Song MJ, Lee SE, Cho SG, Lee JW, Choi JY, Yoon SK, Han NI, Lee YS. A pilot study of autologous CD34-depleted bone marrow mononuclear cell transplantation via the hepatic artery in five patients with liver failure. *Cytotherapy.* 2013;15(12):1571-1579.

18. Song do S, Bae SH, Song MJ, Lee SW, Kim HY, Lee YJ, Oh JS, Chun HJ, Lee HG, Choi JY, Yoon SK. Hepatic arterial infusion chemotherapy in hepatocellular carcinoma with portal vein tumor thrombosis. *World J Gastroenterol.* 2013;19(29):4679-88.

19. Cha JH, Bae SH, Kim HL, Park NR, Choi ES, Jung ES, Choi JY, Yoon SK. Branched-chain amino acids ameliorate fibrosis and suppress tumor growth in a rat model of hepatocellular carcinoma with liver cirrhosis. *PLoS One.* 2013;8(11)

20. Kwon JH, Bae SH, Lee YJ, et al. The virological response in Koreans infected with HCV genotype 1 did not differ between groups treated with a full dose or reduced dose (80 % full dose) of peginterferon alfa-2a: a prospective randomized multicenter trial. *Hepatol Int* 2013(7):1000-1009

(공동저자, 최근 5년간)

Lee SW, Lee HL, Han NI, Kwon JH, Nam SW, Jang JW, Bae SH, Choi JY, Yoon SK. Transarterial infusion of epirubicin and cisplatin combined with systemic infusion of 5-fluorouracil versus transarterial chemoembolization using doxorubicin for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a retrospective analysis. *Ther Adv Med Oncol*. 2017;9(10):615-626.

18. Yang H, Seon J, Sung PS, Oh JS, Lee HL, Jang B, Chun HJ, Jang JW, Bae SH, Choi JY, Yoon SK. Dexamethasone Prophylaxis to Alleviate Postembolization Syndrome after Transarterial Chemoembolization for Hepatocellular Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled Study. *J Vasc Interv Radiol*. 2017;28(11):1503-1511.e2.

19. Chung E, Park K, Kim JH, Han NI, Lee YS, Bae SH, Park CH. Development of bronchiolitis obliterans organizing pneumonia during standard treatment of hepatitis C with Peg IFN α 2b. *Korean J Intern Med*. 2017 ;32(6):1098-1100.

20. Lee JH, Tak WY, Lee Y, Heo MK, Song JS, Kim HY, Park SY, Bae SH, Lee JH, Heo J, Kim KH, Bae YS, Kim YJ. Adjuvant immunotherapy with autologous dendritic cells for hepatocellular carcinoma, randomized phase II study. *Oncoimmunology*. 2017 16;6(7):e1328335.

21. Park JG, Tak WY, Park SY, Kweon YO, Jang SY, Lee YR, Bae SH, Jang JY, Kim DY, Lee JS, Suk KT, Kim IH, Lee HJ, Chung WJ, Jang BK, Suh JI, Heo J, Lee WK. Effects of branched-chain amino acids (BCAAs) on the progression of advanced liver disease: A Korean nationwide, multicenter, retrospective, observational, cohort study. *Medicine (Baltimore)*. 2017 ;96(24):e6580.

22. Choi HJ, Kim DG, Na GH, Hong TH, Bae SH, You YK, Choi JY, Yoon SK. The clinical outcomes of patients with portal vein tumor thrombi after living donor liver transplantation. *Liver Transpl*. 2017 ;23(8):1023-1031.



23. Sung PS, Yang H, Na GH, Hwang S, Kang D, Jang JW, Bae SH, Choi JY, Kim DG, Yoon SK, You YK. Long-Term Outcome of Liver Resection Versus Transplantation for Hepatocellular Carcinoma in a Region Where Living Donation is a Main Source. *Ann Transplant.* 2017 5;22:276-284.
24. Ahn DG, Kim HJ, Kang H, Lee HW, Bae SH, Lee JH, Paik YH, Lee JS. Feasibility of α -fetoprotein as a diagnostic tool for hepatocellular carcinoma in Korea. *Korean J Intern Med.* 2016;31(1):46-53.
25. Chon YE, Kim DJ, Kim SG, Kim IH, Bae SH, Hwang SG, Heo J, Jang JW, Lee BS, Kim HJ, Jun DW, Kim KM, Chung WJ, Choi MS, Jang JY, Yim HJ, Tak WY, Yoon KT, Park JY, Han KH, Suk KT, Lee HW, Jang BK, Ahn SH. An Observational, Multicenter, Cohort Study Evaluating the Antiviral Efficacy and Safety in Korean Patients With Chronic Hepatitis B Receiving Pegylated Interferon-alpha 2a (Pegasys): TRACES Study. *Medicine (Baltimore).* 2016 95(14):e3026.
26. Wei L, Zhang M, Xu M, Chuang WL, Lu W, Xie W, Jia Z, Gong G, Li Y, Bae SH, Yang YF, Xie Q, Lin S, Chen X, Niu J, Jia J, Garimella T, Torbeyns A, McPhee F, Treitel M, Yin PD, Mo L. A phase 3, open-label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies with or without ribavirin. *J Gastroenterol Hepatol.* 2016 Nov;31(11):1860-1867.
27. Lee SK, Choi JY, Yeo DM, Lee YJ, Yoon SK, Bae SH, Jang JW, Kim HY, Kim DG, You YK. Risk factors of biliary intervention by imaging after living donor liver transplantation. *World J Gastroenterol.* 2016;22(7):2342-2348.
28. Cho YY, Lee M, Kim HC, Chung JW, Kim YH, Gwak GY, Bae SH, Kim do Y, Heo J, Kim YJ. Radioembolization Is a Safe and Effective Treatment for Hepatocellular Carcinoma with Portal Vein Thrombosis: A Propensity Score Analysis. *PLoS One.* 2016 5;11(5):e0154986
30. Kim E, Lee SW, Kim WH, Bae SH, Han NI, Oh JS, Chun HJ, Lee HG. Transjugular Intrahepatic Portosystemic Shunt Occlusion Complicated with Biliary Fistula Successfully Treated with a Stent Graft: A Case Report. *Iran J Radiol.* 2016 9;13(1):e28993.
31. Jun JH, Choi JH, Bae SH, Oh SH, Kim GJ. Decreased C-reactive protein induces abnormal vascular structure in a rat model of liver dysfunction induced by bile duct ligation. *Clin Mol Hepatol.* 2016 ;22(3):372-381. (공동연구)

32. Jang B, Han JW, Sung PS, Jang JW, Bae SH, Choi JY, Cho YI, Yoon SK. Hemorheological Alteration in Patients Clinically Diagnosed with Chronic Liver Diseases. *J Korean Med Sci.* 2016 ; 31(12):1943-1948.
33. Ok KS, Jeong SH, Jang ES, Kim YS, Lee YJ, Kim IH, Cho SB, Bae SH, Lee HC. The clinical outcomes of chronic hepatitis C in South Korea: A prospective, multicenter cohort study. *Medicine (Baltimore).* 2016 ;95(35):e4594.
34. Song do S, Nam SW, Bae SH, Kim JD, Jang JW, Song MJ, Lee SW, Kim HY, Lee YJ, Chun HJ, You YK, Choi JY, Yoon SK. Outcome of transarterial chemoembolization-based multi-modal treatment in patients with unresectable hepatocellular carcinoma. *World J Gastroenterol.* 2015;21(8):2395-2404.
35. Lee SS, Jeong SH, Jang ES, Kim YS, Lee YJ, Jung EU, Kim IH, Bae SH, Lee HC, Kee MK, Kang C. Prospective cohort study on the outcomes of hepatitis C virus-related cirrhosis in South Korea. *J Gastroenterol Hepatol.* 2015 30(8):1281-7.
36. Jhun JY, Kim HY, Byun JK, Chung BH, Bae SH, Yoon SK, Kim DG, Yang CW, Cho ML, Choi JY. B-cell-associated immune profiles in patients with decompensated cirrhosis. *Scand J Gastroenterol.* 2015 ;50(7):884-91.
37. Jang JW, Kim YW, Lee SW, Kwon JH, Nam SW, Bae SH, Choi JY, Yoon SK, Chung KW. Reactivation of hepatitis B virus in HBsAg-negative patients with hepatocellular carcinoma. *PLoS One.* 2015;10(3):e0122041
38. Hur W, Lee JH, Kim SW, Kim JH, Bae SH, Kim M, Hwang D, Kim YS, Park T, Um SJ, Song BJ, Yoon SK. Downregulation of microRNA-451 in non-alcoholic steatohepatitis inhibits fatty acid-induced proinflammatory cytokine production through the AMPK/AKT pathway. *Int J Biochem Cell Biol.* 2015;64:265-276.
39. Korean Liver Cancer Study Group (KLCSG); National Cancer Center, Korea (NCC). 2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma. *Korean J Radiol.* 2015 ;16(3):465-522.
40. Lee SS, Jeong SH, Jang ES, Kim YS, Lee YJ, Jung EU, Kim IH, Bae SH, Lee HC.



Treatment rate and factors related to interferon-based treatment initiation for chronic hepatitis C in South Korea. *J Med Virol.* 2016 ;88(2):275-81.

41. Han JW, Yang H, Lee HL, Bae SH, Choi JY, Lee JW, Kim HJ, Lee S, Cho SG, Min CK, Kim DW, Yoon SK. Risk factors and outcomes of hepatitis B virus reactivation in hepatitis B surface antigen negative patients with hematological malignancies. *Hepato Res.* 2016 Jun;46:657-68.

42. Kwon JH, Jang JW, Kim YW, Lee SW, Nam SW, Jaegal D, Lee S, Bae SH. The usefulness of C-reactive protein and neutrophil-to-lymphocyte ratio for predicting the outcome in hospitalized patients with liver cirrhosis. *BMC Gastroenterol.* 2015 23;15:146.

43. Yoon SK, Seo YB, Im SJ, Bae SH, Song MJ, You CR, Jang JW, Yang SH, Suh YS, Song JS, Kim BM, Kim CY, Jeong SH, Sung YC. Safety and immunogenicity of therapeutic DNA vaccine with antiviral drug in chronic HBV patients and its immunogenicity in mice. *Liver Int.* 2015 ;35(3):805-15.

44. Kim HY, Kim CW, Lee CD, Choi JY, Park CH, Bae SH, Yoon SK, Han K, Park YM. Can "healthy" normal alanine aminotransferase levels identify the metabolically obese phenotype? Findings from the Korea national health and nutrition examination survey 2008-2010. *Dig Dis Sci.* 2014 ;59(6):1330-7.

45. Kim HY, Choi JY, Park CH, Song MJ, Song DS, Kim CW, Bae SH, Yoon SK, Lee YJ, Rha SE. Clinical factors predictive of insufficient liver enhancement on the hepatocyte-phase of Gd-EOB-DTPA-enhanced magnetic resonance imaging in patients with liver cirrhosis. *J Gastroenterol.* 2013;18(7):850-7.

46. Song DS, Choi JY, Yoo SH, Kim HY, Song MJ, Bae SH, Yoon SK, Chun HJ, Choi BG, Lee HG. DC Bead Transarterial Chemoembolization Is Effective in Hepatocellular Carcinoma Refractory to Conventional Transarterial Chemoembolization: A Pilot Study. *Gut Liver.* 2013;7(1):89-95.

47. Yoo SH, Choi JY, Jang JW, Bae SH, Yoon SK, Kim DG, Yoo YK, Rha SE, Lee YJ, Jung ES. Gd-EOB-DTPA-Enhanced MRI is Better than MDCT in Decision Making of Curative Treatment for Hepatocellular Carcinoma. *Ann Surg Oncol.* 2013;20(9):2893-2900

48. Seo JY, Choi BY, Ki M, Jang HL, Park HS, Son HJ, Bae SH, Kang JH, Jun DW, Lee JW, Hong YJ, Kim YS, Kim CH, Chang UI, Kim JH, Yang HW, Kim HS, Park KB, Hwang JS, Heo J, Kim IH,

Kim JS, Cheon GJ. Risk factors for acute hepatitis A infection in Korea in 2007 and 2009: a case-control study. *J Korean Med Sci.* 2013;28(6):908-14.

49. Seong MH, Kil H, Kim JY, Lee SS, Jang ES, Kim JW, Jeong SH, Kim YS, Bae SH, Lee YJ, Lee HC, Yun H, Kang BH, Kim K. Clinical and epidemiological characteristics of Korean patients with hepatitis C virus genotype 6. *Clin Mol Hepatol.* 2013;19(1):45-50.

50. Chen DS, Locarnini S, Wait S, Bae SH, Chen PJ, Fung JY, Kim HS, Lu SN, Sung J, Tanaka J, Wakita T, Ward J, Wallace J; CEVHAP North Asia Workshop on Viral Hepatitis. Report from a Viral Hepatitis Policy Forum on Implementing the WHO Framework for Global Action on Viral Hepatitis in North Asia. *J Hepatol.* 2013;59(5):1073-80.